Search

everythinglearnresearchcommunity

for

Search:↓

A 21-year-old male is experiencing potential hair regrowth after using minoxidil, finasteride, microneedling, and ketoconazole shampoo. Users are optimistic about his progress, advising patience and consistency.

A user is seeking a hair loss formula containing Redensyl and Capixyl without caffeine, Saw Palmetto, or other herbs. They want recommendations for such a product.

KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.

The conversation is about finding the best method to lower scalp prolactine, with suggestions like P5P and Melatonin. The user also mentions HMI115 as a potential treatment and seeks feedback from those who have tried these methods.

Hair cloning and injection of dermal papilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.

Stemson Therapeutics will start human trials for hair cloning in late 2025-2026. Product development is complete, and they are preparing for production and clinical trials.

The conversation is about the long-term use of RU58841 for hair loss, with users sharing their experiences and seeking information on its effectiveness and whether it needs to be used continuously like minoxidil or finasteride.

The user is experiencing hair loss and is using oral finasteride, considering adding RU58841 and microneedling, and planning a hair transplant. They are seeking advice on whether to wait for treatment results or proceed with the transplant.

The conversation discusses the results of a group buy for Ky19382 related to hair loss treatments. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.